Allergy point-of-care testing market seen reaching $2.34 billion by 2030

The global allergy point-of-care testing market is forecast to grow from $1.33 billion in 2025 to $2.34 billion by 2030, driven by rising allergic disease rates, faster diagnostics and broader use of decentralized testing. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Allergy point-of-care testing can speed diagnosis at the patient site, helping clinicians identify triggers and start treatment sooner. - The market is expanding as allergic disorders become more common and healthcare systems push for faster, more convenient diagnostics. - Growth in home-based and outpatient testing could reduce reliance on centralized laboratories.

What happened: - The Business Research Company said the global allergy point-of-care testing market rose from $1.33 billion in 2025 to $1.49 billion in 2026. - The company projects the market will reach $2.34 billion by 2030. - The forecast implies a 12.0% compound annual growth rate from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Allergy point-of-care testing uses quick diagnostic methods performed at or near the point of care to detect allergic sensitizations. - These tests measure specific immunoglobulin E, or IgE, antibodies or other biomarkers linked to allergic reactions. - The market’s recent growth has been supported by rising allergic disorders, earlier diagnosis efforts, immunoassay advances, hospital lab expansion and more pediatric allergy cases. - The report points to broader adoption of point-of-care diagnostics, personalized allergy management, AI-driven interpretation and more outpatient care as key drivers through 2030. - Rapid IgE tests, portable point-of-care devices, decentralized screening in primary care, rapid detection kits and digital health integration are listed as major trends. - A free sample report is available here. - The full report is available here. - The report also covers South East Asia, Western Europe, Eastern Europe, South America and the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - Rising allergy burden is translating into demand for faster testing, not just more testing. - Higher healthcare spending is helping create room for diagnostic tools that can shift care away from central labs and into clinics, primary care and home settings. - The market opportunity is not only about test volume. It is also about workflow changes, digital interpretation and broader access. - In January 2026, the US Centers for Medicare & Medicaid Services said National Health Expenditure rose 7.2% to $5.3 trillion in 2024, or $15,474 per person, equal to 18.0% of GDP. - In November 2025, Asthma Australia reported 322 women died from asthma in the previous year, compared with 156 men, with half of 478 total asthma-related deaths occurring among women aged 75 and older.

What's next: - Adoption of rapid IgE testing and portable devices is expected to accelerate as providers look for faster allergy screening tools. - The market is likely to benefit from more decentralized care settings, including primary care and outpatient services. - AI-assisted interpretation and digital health platforms may become more embedded in testing workflows as the category matures.

The bottom line: - Allergy point-of-care testing is moving from a niche diagnostic tool toward a faster, more distributed testing model backed by rising allergy prevalence and higher healthcare investment.